Sandbox ID Musculoskeletal: Difference between revisions

Jump to navigation Jump to search
 
(103 intermediate revisions by 4 users not shown)
Line 1: Line 1:
===Bursitis===
===Bursitis===


* Olecranon bursitis or prepatellar bursitis
* Olecranon bursitis or prepatellar bursitis <ref>{{cite book | last = Gilbert | first = David | title = The Sanford guide to antimicrobial therapy | publisher = Antimicrobial Therapy | location = Sperryville, Va | year = 2015 | isbn = 978-1930808843 }}</ref>
:* Staphylococcus aureus, methicillin-susceptible (MSSA)
:*1. '''Staphylococcus aureus, methicillin-susceptible (MSSA)'''
::* Preferred regimen: [[Nafcillin]] 2 g IV q4h {{or}} [[Oxacillin]] 2 g IV q4h {{or}} [[Dicloxacillin]] 500 mg PO qid
::* Preferred regimen (1): [[Nafcillin]] 2 g IV q4h
:* Staphylococcus aureus, methicillin-resistant (MRSA)
 
::* Preferred regimen: [[Vancomycin]] 1 g IV q12h {{or}} [[Linezolid]] 600 mg PO qd
::* Preferred regimen (2): [[Oxacillin]] 2 g IV q4h
::: Note: Initially aspirate q24h and treat for a minimum of 2–3 weeks.
 
::* Preferred regimen (3): [[Dicloxacillin]] 500 mg PO qid
:*2. '''Staphylococcus aureus, methicillin-resistant (MRSA)'''
::* Preferred regimen (1): [[Vancomycin]] 1 g IV q12h  
 
::* Preferred regimen (2): [[Linezolid]] 600 mg PO qd


===Osteomyelitis, candidal===
===Osteomyelitis, candidal===
* Osteomyelitis, candidal <ref name="pmid19191635">{{cite journal| author=Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE et al.| title=Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. | journal=Clin Infect Dis | year= 2009 | volume= 48 | issue= 5 | pages= 503-35 | pmid=19191635 | doi=10.1086/596757 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19191635  }} </ref>
* Osteomyelitis, candidal <ref name="pmid19191635">{{cite journal| author=Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE et al.| title=Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. | journal=Clin Infect Dis | year= 2009 | volume= 48 | issue= 5 | pages= 503-35 | pmid=19191635 | doi=10.1086/596757 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19191635  }} </ref>
:* Preferred regimen: Fluconazole 400 mg (6 mg/kg) daily for 6–12 months {{or}} lipid formulation of amphotericin B 3–5 mg/kg daily for several weeks, then fluconazole for 6–12 months
:* Preferred regimen (1): [[Fluconazole]] 400 mg/day (6 mg/kg/day) PO for 6–12 months   
 
:* Preferred regimen (2): [[Amphotericin B]] 3–5 mg/kg/day PO for several weeks {{then}} [[Fluconazole]] for 6–12 months
:* Alternative regimen (1): [[Anidulafungin]] 200 mg loading dose {{then}} 100 mg/day PO
 
:* Alternative regimen (2): [[Caspofungin]] 70mg loading dose {{then}} 50 mg/day PO 


:* Alternative regimen (1): (Anidulafungin 200-mg loading dose, then 100 mg/day {{or}} Caspofungin, 70-mg loading dose, then 50 mg/day {{or}} Micafungin 100 mg/day), then fluconazole for 6–12 months
:* Alternative regimen (3): [[Micafungin]] 100 mg/day PO
:* Alternative regimen (2): Amphotericin B deoxycholate 0.5–1 mg/kg daily for several weeks, then Fluconazole for 6–12 months
:* Alternative regimen (4): [[Amphotericin B]] deoxycholate 0.5–1 mg/kg/day PO for several weeks {{then}} [[Fluconazole]] for 6–12 months
: NOTE: Duration of therapy usually is prolonged (6–12 months); Surgical debridement is frequently necessary
:* Note: Duration of therapy usually is prolonged (6–12 months); Surgical debridement is frequently necessary


===Osteomyelitis, chronic===
===Osteomyelitis, chronic===
*Chronic Osteomyelitis in Adults – Pathogen-Based Therapy
*1. '''Chronic Osteomyelitis in Adults – Pathogen-Based Therapy''' <ref name="pmid22157324">{{cite journal| author=Spellberg B, Lipsky BA| title=Systemic antibiotic therapy for chronic osteomyelitis in adults. | journal=Clin Infect Dis | year= 2012 | volume= 54 | issue= 3 | pages= 393-407 | pmid=22157324 | doi=10.1093/cid/cir842 | pmc=PMC3491855 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22157324  }} </ref>
:*1.1 '''OSSA'''
::* Preferred regimen (1): [[Oxacillin]] 1.5–2 g IV q4h for 4–6 weeks
::* Preferred regimen (2): [[Cefazolin]] 1–2 g IV q8h for 4–6 weeks
::* Alternative regimen (1): [[Vancomycin]] 15 mg/kg IV q12h for 4–6 weeks
::* Alternative regimen (2): [[Oxacillin]] 1.5–2 g IV q4h for 4–6 weeks {{and}} [[Rifampin]] 600 mg PO qd
:*1.2 '''ORSA'''
::* Preferred regimen (1): [[Vancomycin]] 15 mg/kg IV q12h for 4–6 weeks
::* Preferred regimen (2): [[Daptomycin]] 6 mg/kg IV q24h
::* Alternative regimen (1): [[Linezolid]] 600 mg PO/IV q12h for 6 weeks {{withorwithout}} [[Rifampin]] 600–900 mg PO qd
::* Alternative regimen (2): [[Levofloxacin]] 500–750 mg/day PO/IV {{withorwithout}} [[Rifampin]] 600–900 mg PO qd
:*1.3 '''Penicillin-sensitive Streptococcus'''
::* Preferred regimen (1): [[Penicillin G]] 20 MU/day IV continuously or q4h for 4–6 weeks 
 
::* Preferred regimen (2): [[Ceftriaxone]] 1–2 g IV/IM q24h for 4–6 weeks 
 
::* Preferred regimen (3): [[Cefazolin]] 1–2 g IV q8h for 4–6 weeks
::* Alternative regimen: [[Vancomycin]] 15 mg/kg IV q12h for 4–6 weeks
:*1.4 '''Enterococcus or Streptococcus (MIC≥ 0.5 μg/mL) or Abiotrophia or Granulicatella'''
::* Preferred regimen (1): [[Penicillin G]] 20 MU/day IV continuously or q4h for 4–6 weeks {{withorwithout}} [[Gentamicin]] 1 mg/kg IV/IM q8h for 1–2 weeks


:*OSSA
::* Preferred regimen (2): [[Ampicillin]] 12 g/day IV continuously or q4h for 4–6 weeks {{withorwithout}} [[Gentamicin]] 1 mg/kg IV/IM q8h for 1–2 weeks
::* Preferred regimen: Oxacillin 1.5–2 g IV q4h for 4–6 wk {{or}} Cefazolin 1–2 g IV q8h for 4–6 wk
::* Alternative regimen: [[Vancomycin]] 15 mg/kg IV q12h for 4–6 weeks {{withorwithout}} [[Gentamicin]] 1 mg/kg IV/IM q8h for 1–2 weeks
:*1.5 '''Enterobacteriaceae'''
::* Preferred regimen (1): [[Ceftriaxone]] 1–2 g IV/IM q24h for 4–6 weeks


::* Alternative regimen (1): Vancomycin 15 mg/kg IV q12h for 4–6 wk
::* Preferred regimen (2): [[Ertapenem]] 1 g IV q24h
::* Alternative regimen (2): Oxacillin 1.5–2 g IV q4h for 4–6 wk {{and}} Rifampin 600 mg PO qd
::* Alternative regimen (1): [[Levofloxacin]] 500–750 mg PO qd


:*ORSA
::* Alternative regimen (2): [[Ciprofloxacin]] 500–750 mg PO bid for 4–6 weeks
::* Preferred regimen: Vancomycin 15 mg/kg IV q12h for 4–6 wk {{or}} Daptomycin 6 mg/kg IV q24h
:*1.6 '''Pseudomonas aeruginosa'''
::* Alternative regimen (1): Linezolid 600 mg PO/IV q12h for 6 wk {{withorwithout}} Rifampin 600–900 mg PO qd
::* Preferred regimen (1): [[Cefepime]] 2 g IV q12h
::* Alternative regimen (2): Levofloxacin 500–750 mg PO/IV daily {{withorwithout}} Rifampin 600–900 mg PO qd
:*Penicillin-sensitive Streptococcus
::* Preferred regimen: Penicillin G 20 MU/day IV continuously or q4h for 4–6 wk {{or}} Ceftriaxone 1–2 g IV/IM q24h for 4–6 wk {{or}} Cefazolin 1–2 g IV q8h for 4–6 wk
::* Alternative regimen: Vancomycin 15 mg/kg IV q12h for 4–6 wk


:*Enterococcus or Streptococcus (MIC≥0.5 μg/mL) or Abiotrophia or Granulicatella
::* Preferred regimen (2): [[Meropenem]] 1 g IV q8h
::* Preferred regimen: Penicillin G 20 MU/day IV continuously or q4h for 4–6 wk {{withorwithout}} Gentamicin 1 mg/kg IV or IM q8h for 1–2 wk {{or}} Ampicillin 12 g/day IV continuously or q4h for 4–6 wk {{withorwithout}} Gentamicin 1 mg/kg IV or IM q8h for 1–2 wk


::* Alternative regimen: Vancomycin 15 mg/kg IV q12h for 4–6 wk {{withorwithout}} Gentamicin 1 mg/kg IV or IM q8h for 1–2 wk
::* Preferred regimen (3): [[Imipenem]] 500 mg IV q6h for 4–6 weeks
:*Enterobacteriaceae
::* Alternative regimen (1): [[Ciprofloxacin]] 750 mg PO q12h
::* Preferred regimen: Ceftriaxone 1–2 g IV/IM q24h for 4–6 wk {{or}} Ertapenem 1 g IV q24h
::* Alternative regimen: Levofloxacin 500–750 mg PO q24h {{or}} Ciprofloxacin 500–750 mg PO q12h for 4–6 wk
:*Pseudomonas aeruginosa
::* Preferred regimen: Cefepime 2 g IV q12h {{or}} Meropenem 1 g IV q8h {{or}} Imipenem 500 mg IV q6h for 4–6 wk
::* Alternative regimen: Ciprofloxacin 750 mg PO q12h {{or}} Ceftazidime 2 g IV q8h for 4–6 wk


* Chronic Osteomyelitis in Children – Pathogen-Based Therapy
::* Alternative regimen (2): [[Ceftazidime]] 2 g IV q8h for 4–6 weeks
:* ''Group A beta-hemolytic Streptococcus, Haemophilus influenzae type b, andStreptococcus pneumoniae''
::* Preferred regimen: Ampicillin 150–200 mg/kg/day administered in 4 equal doses {{or}} Amoxicillin 150–200 mg/kg/day administered in 4 equal doses


::* Alternative regimen: Chloramphenicol 75 mg/kg/day administered in 3 equal doses
*2. '''Chronic Osteomyelitis in Children – Pathogen-Based Therapy'''
:* ''Group A beta-hemolytic Streptococcus, Haemophilus influenzae type B and Streptococcus pneumoniae''
::* Preferred regimen (1): [[Ampicillin]] 150–200 mg/kg/day q6h
 
::* Preferred regimen (2): [[Amoxicillin]] 150–200 mg/kg/day q6h
::* Alternative regimen: [[Chloramphenicol]] 75 mg/kg/day q8h


===Osteomyelitis, contiguous with vascular insufficiency===
===Osteomyelitis, contiguous with vascular insufficiency===


* Osteomyelitis, contiguous with vascular insufficiency
* Osteomyelitis, contiguous with vascular insufficiency <ref>{{cite book | last = Gilbert | first = David | title = The Sanford guide to antimicrobial therapy | publisher = Antimicrobial Therapy | location = Sperryville, Va | year = 2015 | isbn = 978-1930808843 }}</ref>
:* Debride overlying ulcer and send bone specimen for histology and culture.  
:* Debride overlying ulcer and send bone specimen for histology and culture.  
:* No empiric antimicrobial therapy unless acutely ill.
:* No empiric antimicrobial therapy unless acutely ill.
Line 59: Line 83:


===Osteomyelitis, diabetic foot===
===Osteomyelitis, diabetic foot===
* Chronic Infection or Recent Antibiotic Use
*1. '''Chronic Infection or Recent Antibiotic Use''' <ref name="pmid23328846">{{cite journal| author=Lipsky BA, Berendt AR, Cornia PB, Pile JC, Peters EJ, Armstrong DG et al.| title=2012 infectious diseases society of america clinical practice guideline for the diagnosis and treatment of diabetic foot infections. | journal=J Am Podiatr Med Assoc | year= 2013 | volume= 103 | issue= 1 | pages= 2-7 | pmid=23328846 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23328846  }} </ref>
:* Preferred regimen: Levofloxacin 750 mg IV/PO q24h {{or}} Cefoxitin 1 g IV q4h (or 2 g IV q6–8h) {{or}} Ceftriaxone 1–2 g/day IV/IM q12–24h {{or}} Ampicillin–Sulbactam 1.5–3 g IV/IM q6h {{or}} Moxifloxacin 400 mg IV/PO q24h {{or}} Ertapenem 1 g IV/IM q24h {{or}} Tigecycline 100 mg IV, then 50 mg IV q12h (active against MRSA) {{or}} Imipenem–Cilastatin 0.5–1 g IV q6–8h (Not active against MRSA; consider when ESBL-producing pathogens suspected)
:* Preferred regimen (1): [[Levofloxacin]] 750 mg IV/PO q24h  


:* Alternative regimen (1): Levofloxacin 750 mg IV/PO q24h {{and}} Clindamycin 150–300 mg PO qid
:* Preferred regimen (2): [[Cefoxitin]] 1 g IV q4h (or 2 g IV q6–8h)
:* Alternative regimen (2): Ciprofloxacin 600–1200 mg/day IV q6–12h {{and}} Clindamycin 150–300 mg PO qid


:* Alternative regimen (3): Ciprofloxacin 1200–2700 mg IV q6–12h (for more severe cases) {{and}} Clindamycin 150–300 mg PO qid
:* Preferred regimen (3): [[Ceftriaxone]] 1–2 g/day IV/IM q12–24h 


* High Risk for MRSA
:* Preferred regimen (4): [[Ampicillin-Sulbactam]] 1.5–3 g IV/IM q6h 
:* Preferred regimen: Linezolid 600 mg IV/PO q12h {{or}} Daptomycin 4 mg/kg IV q24h {{or}} Vancomycin 15–20 mg/kg IV q8–12h (trough: 10–20 mg/L)


* High Risk for ''Pseudomonas aeruginosa''
:* Preferred regimen (5): [[Moxifloxacin]] 400 mg IV/PO q24h


:* Preferred regimen: Piperacillin–Tazobactam 3.375 g IV q6–8h
:* Preferred regimen (6): [[Ertapenem]] 1 g IV/IM q24h 


* Polymicrobial Infection
:* Preferred regimen (7): [[Tigecycline]] 100 mg IV {{then}} 50 mg IV q12h (active against MRSA)


:* Preferred regimen: (Vancomycin 15–20 mg/kg IV q8–12h (trough: 10–20 mg/L) {{or}} Linezolid 600 mg IV/PO q12h {{or}} Daptomycin 4 mg/kg IV q24h) {{and}} (Piperacillin–Tazobactam 3.375 g IV q6–8h {{or}} Imipenem–Cilastatin 0.5–1 g IV q6–8h {{or}} Ertapenem 1 g IV/IM q24h {{or}} Meropenem 1 g IV q8h)
:* Preferred regimen (8): [[Imipenem-Cilastatin]] 0.5–1 g IV q6–8h (Not active against MRSA; consider when ESBL-producing pathogens suspected)
:* Alternative regimen: (Vancomycin 15–20 mg/kg IV q8–12h (trough: 10–20 mg/L) {{or}} Linezolid 600 mg IV/PO q12h {{or}} Daptomycin 4 mg/kg IV q24h) {{and}} (Ceftazidime 2 g IV q8h {{or}} Cefepime 2 g IV q8h {{or}} Aztreonam 2 g IV q6–8h) {{and}} Metronidazole 15 mg/kg IV, then 7.5 mg/kg IV q6h
:* Alternative regimen (1): [[Levofloxacin]] 750 mg IV/PO q24h {{and}} [[Clindamycin]] 150–300 mg PO qid
:* Alternative regimen (2): [[Ciprofloxacin]] 600–1200 mg/day IV q6–12h {{and}} [[Clindamycin]] 150–300 mg PO qid
:* Alternative regimen (3): [[Ciprofloxacin]] 1200–2700 mg IV q6–12h (for more severe cases) {{and}} [[Clindamycin]] 150–300 mg PO qid
*2. '''High Risk for MRSA'''
:* Preferred regimen (1): [[Linezolid]] 600 mg IV/PO q12h
 
:* Preferred regimen (2): [[Daptomycin]] 4 mg/kg IV q24h 
 
:* Preferred regimen (3): [[Vancomycin]] 15–20 mg/kg IV q8–12h (trough: 10–20 mg/L)
*3. '''High Risk for ''Pseudomonas aeruginosa'''
:* Preferred regimen: [[Piperacillin–Tazobactam]] 3.375 g IV q6–8h
*4. '''Polymicrobial Infection'''
:* Preferred regimen: ([[Vancomycin]] 15–20 mg/kg IV q8–12h (trough: 10–20 mg/L) {{or}} [[Linezolid]] 600 mg IV/PO q12h {{or}} [[Daptomycin]] 4 mg/kg IV q24h) {{and}} ([[Piperacillin–Tazobactam]] 3.375 g IV q6–8h {{or}} [[Imipenem]]–Cilastatin 0.5–1 g IV q6–8h {{or}} [[Ertapenem]] 1 g IV/IM q24h {{or}} [[Meropenem]] 1 g IV q8h)
:* Alternative regimen: ([[Vancomycin]] 15–20 mg/kg IV q8–12h (trough: 10–20 mg/L) {{or}} [[Linezolid]] 600 mg IV/PO q12h {{or}} [[Daptomycin]] 4 mg/kg IV q24h) {{and}} ([[Ceftazidime]] 2 g IV q8h {{or}} [[Cefepime]] 2 g IV q8h {{or}} [[Aztreonam]] 2 g IV q6–8h) {{and}} [[Metronidazole]] 15 mg/kg IV, then 7.5 mg/kg IV q6h


===Osteomyelitis, foot bone===
===Osteomyelitis, foot bone===
* Foot bone osteomyelitis due to nail through tennis shoe <ref>{{cite book | last = Gilbert | first = David | title = The Sanford guide to antimicrobial therapy | publisher = Antimicrobial Therapy | location = Sperryville, Va | year = 2015 | isbn = 978-1930808843 }}</ref>
:* Preferred regimen (1): [[Ciprofloxacin]] 750 mg PO bid 
:* Preferred regimen (2): [[Levofloxacin]] 750 mg PO q24h
:* Alternative regimen (1): [[Ceftazidime]] 2 g IV q8h
:* Alternative regimen (2): [[Cefepime]] 2 g IV q12h


===Osteomyelitis, foot puncture wound===
===Osteomyelitis, foot puncture wound===
* Long bone, post-internal fixation of fracture <ref>{{cite book | last = Gilbert | first = David | title = The Sanford guide to antimicrobial therapy | publisher = Antimicrobial Therapy | location = Sperryville, Va | year = 2015 | isbn = 978-1930808843 }}</ref>
:*1. '''S. aureus  or  P. aeruginosa'''
::* Preferred regimen: [[Vancomycin]] 1 g IV q12h {{and}} ([[Ceftazidime]] {{or}} [[Cefepime]])
::* Alternative regimen (1): [[Linezolid]] 600 mg IV/PO bid<sup>NAI</sup> {{and}} [[Ceftazidime]]
::* Alternative regimen (2): [[Linezolid]] 600 mg IV/PO bid<sup>NAI</sup> {{and}} [[Cefepime]]
:*2. '''Gm-neg. bacilli '''
::* Preferred regimen (1): [[Ciprofloxacin]] 750 mg po bid 
::* Preferred regimen (2): [[Levofloxacin]] 750 mg po qd


===Osteomyelitis, hematogenous===
===Osteomyelitis, hematogenous===
* Empiric therapy
*1. '''Empiric therapy''' <ref>{{cite book | last = Gilbert | first = David | title = The Sanford guide to antimicrobial therapy | publisher = Antimicrobial Therapy | location = Sperryville, Va | year = 2015 | isbn = 978-1930808843 }}</ref>
:* Adult (>21 yrs)
:*1.1 '''Adult (>21 yrs)'''
::* MRSA possible
::*1.1.1 '''MRSA possible'''
:::* Preferred regimen: Vancomycin 1 gm IV q12h (if over 100 kg, 1.5 gm IV q12h)
:::* Preferred regimen: [[Vancomycin]] 1 g IV q12h (if over 100 kg, 1.5 g IV q12h)
::* MRSA unlikely  
::*1.1.2 '''MRSA unlikely'''
:::* Preferred regimen: Nafcillin {{or}} Oxacillin 2 gm IV q4h
:::* Preferred regimen: [[Nafcillin]] {{or}} [[Oxacillin]] 2 g IV q4h
:*1.2 '''Children (>4 mos.)-Adult'''
::*1.2.1 '''MRSA possible'''
:::* Preferred regimen: [[Vancomycin]] 40 div q6–8h
::*1.2.2 '''MRSA unlikely'''
:::* Preferred regimen: [[Nafcillin]] {{or}} [[Oxacillin]] 37 q6h (to max. 8–12 g per day)
::* Note: Add [[Ceftazidime]] 50 q8h or [[Cefepime]] 150 div q8h if Gm-neg. bacilli on Gram stain 
:*1.3 '''Newborn (<4 mos.)'''
::*1.3.1 '''MRSA possible'''
:::* Preferred regimen: [[Vancomycin]] {{and}} ([[Ceftazidime]] 2 g IV q8h or [[Cefepime]] 2 g IV q12h)
::*1.3.2 '''MRSA unlikely'''
:::* Preferred regimen: ([[Nafcillin]] {{or}} [[Oxacillin]]) {{and}} ([[Ceftazidime]] {{or}} [[Cefepime]])
*2. '''Specific therapy'''
:*2.1 '''MSSA'''
::* Preferred regimen: [[Nafcillin]] {{or}} [[Oxacillin]] 2 g IV q4h {{or}} [[Cefazolin]] 2 g IV q8h
::* Alternative regimen: [[Vancomycin]] 1 g IV q12h (if over 100 kg, 1.5 g IV q12h)
:*2.2 '''MRSA'''
::* Preferred regimen: [[Vancomycin]] 1 g IV q12h
::* Alternative regimen: [[Linezolid]] 600 mg q12h IV/po {{withorwithout}} [[Rifampin]] 300 mg po/IV bid
 
===Osteomyelitis, hemoglobinopathy===
* Osteomyelitis, hemoglobinopathy <ref>{{cite book | last = Gilbert | first = David | title = The Sanford guide to antimicrobial therapy | publisher = Antimicrobial Therapy | location = Sperryville, Va | year = 2015 | isbn = 978-1930808843 }}</ref>
:* Preferred regimen: [[Ciprofloxacin]] 400 mg IV q12h
:* Alternative regimen: [[Levofloxacin]] 750 mg IV q24h
 
===Osteomyelitis, spinal implant===
*1. '''Onset within 30 days''' <ref>{{cite book | last = Gilbert | first = David | title = The Sanford guide to antimicrobial therapy | publisher = Antimicrobial Therapy | location = Sperryville, Va | year = 2015 | isbn = 978-1930808843 }}</ref> <ref name="pmid17342641">{{cite journal| author=Kowalski TJ, Berbari EF, Huddleston PM, Steckelberg JM, Mandrekar JN, Osmon DR| title=The management and outcome of spinal implant infections: contemporary retrospective cohort study. | journal=Clin Infect Dis | year= 2007 | volume= 44 | issue= 7 | pages= 913-20 | pmid=17342641 | doi=10.1086/512194 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17342641  }} </ref>
:* Culture, treat & then suppress until fusion occurs
::* Main parenteral antimicrobial therapy
:::* Preferred regimen: [[Beta-lactam antibiotic]] {{or}} [[Vancomycin]]
 
::* Suppressive antimicrobial therapy strategy
:::* Preferred regimen: [[Beta-lactam antibiotic]] {{or}} [[Minocycline]]
*2. '''Onset after 30 days'''
:* Remove implant, culture & treat
::* Main parenteral antimicrobial therapy
:::* Preferred regimen: [[Beta-lactam antibiotic]] {{or}} [[Vancomycin]] {{or}} Combination therapy
::* Suppressive antimicrobial therapy strategy
:::* Preferred regimen: Combination therapy {{or}} [[Minocycline]]
 
===Osteomyelitis, vertebral===
 
* Vertebral Osteomyelitis – Pathogen-Based Therapy <ref name="pmid2024868">{{cite journal| author=Gentry LO| title=Oral antimicrobial therapy for osteomyelitis. | journal=Ann Intern Med | year= 1991 | volume= 114 | issue= 11 | pages= 986-7 | pmid=2024868 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2024868  }} </ref> <ref name="pmid21427393">{{cite journal| author=Marschall J, Bhavan KP, Olsen MA, Fraser VJ, Wright NM, Warren DK| title=The impact of prebiopsy antibiotics on pathogen recovery in hematogenous vertebral osteomyelitis. | journal=Clin Infect Dis | year= 2011 | volume= 52 | issue= 7 | pages= 867-72 | pmid=21427393 | doi=10.1093/cid/cir062 | pmc=PMC3106232 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21427393  }} </ref>
:*1. '''OSSA or coagulase-negative staphylococci'''
::* Preferred regimen (1): [[Oxacillin]] 2 g IV q6h 


:* Children (>4 mos.)-Adult
::* Preferred regimen (2): [[Cefazolin]] 1–2 g IV q8h
::* MRSA possible
::* Alternative regimen: [[Levofloxacin]] 750 mg PO qd {{and}} [[Rifampin]] 300 mg PO bid
:::* Preferred regimen: Vancomycin
:*2. '''ORSA'''
::* MRSA unlikely
::* Preferred regimen: [[Vancomycin]] 1 g IV q12h
:::* Preferred regimen: Nafcillin {{or}} Oxacillin
::* Alternative regimen (1): [[Daptomycin]] 6 mg/kg IV q24h
::* NOTE: Add Ceftazidime or Cefepime if Gm-neg. bacilli on Gram stain 
::* Alternative regimen (2): [[Levofloxacin]] 500–750 mg/day PO/IV {{and}} [[Rifampin]] 600–900 mg PO qd
:*3. '''Streptococcus'''
::* Preferred regimen: [[Penicillin G]] 5 MU IV q6h
::* Alternative regimen: [[Ceftriaxone]] 2 g IV q24h
:*4. '''Enterobacteriaceae, quinolone-susceptible'''
::* Preferred regimen: [[Ciprofloxacin]] 750 mg PO q12h
::* Alternative regimen: [[Ceftriaxone]] 2 g IV q24h
:*5. '''Enterobacteriaceae, quinolone-resistant'''
::* Preferred regimen: [[Imipenem]] 500 mg IV q6h
:*6. '''Pseudomonas aeruginosa'''
::* Preferred regimen: ([[Cefepime]] 2 g IV q8h {{or}} [[Ceftazidime]] 2 g IV q8h for 2–4 weeks), followed by [[Ciprofloxacin]] 750 mg PO bid
::* Alternative regimen: [[Piperacillin–Tazobactam]] 750 mg PO q12h for 2–4 weeks, followed by [[Ciprofloxacin]] 750 mg PO bid
:*7. '''Anaerobes'''
::* Preferred regimen: [[Piperacillin–Tazobactam]] 750 mg PO q12h for 2–4 weeks, followed by [[Ciprofloxacin]] 750 mg PO bid
::* Alternative regimen (1): [[Penicillin G]] 5 MU IV q6h


:* Newborn (<4 mos.)
::* Alternative regimen (2): [[Ceftriaxone]] 2 g IV q24h (against gram-positive anaerobes)
::* MRSA possible
::* Alternative regimen (3): [[Metronidazole]] 500 mg PO tid (against gram-negative anaerobes)
:::* Preferred regimen: Vancomycin {{and}} (Ceftazidime 2 gm IV q8h or Cefepime 2 gm IV q12h)  
::* MRSA unlikely
:::* Preferred regimen: (Nafcillin {{or}} Oxacillin) {{and}} (Ceftazidime {{or}} Cefepime)  


* Specific therapy
===Osteomyelitis, sternal===
:* MSSA
* Osteomyelitis, sternal <ref>{{cite book | last = Gilbert | first = David | title = The Sanford guide to antimicrobial therapy | publisher = Antimicrobial Therapy | location = Sperryville, Va | year = 2015 | isbn = 978-1930808843 }}</ref>
::* Preferred regimen:
:* Preferred regimen: [[Vancomycin]] 1 g IV q12h (If over 100kg, 1.5 g IV q12h)
::* Alternative regimen:
:* Alternative regimen: [[Linezolid]] 600 mg po/IV<sup>NAI</sup> bid
:* MRSA
::* Preferred regimen:
::* Alternative regimen:


===Osteomyelitis, hemoglobinopathy===
===Osteonecrosis of the jaw===
:* Preferred regimen: Ciprofloxacin 400 mg IV q12h
*1. '''Bacterial Infection''' <ref>{{cite book | last = Gilbert | first = David | title = The Sanford guide to antimicrobial therapy | publisher = Antimicrobial Therapy | location = Sperryville, Va | year = 2015 | isbn = 978-1930808843 }}</ref>
:* Preferred regimen (1): [[Penicillin]] VK 500 mg PO q6–8h for 7–10 days (maintenance: 500 mg PO bid)


:* Alternative regimen: Levofloxacin 750 mg IV q24h
:* Preferred regimen (2): [[Amoxicillin]] 500 mg PO q8h for 7–10 days (maintenance: 500 mg PO bid)
:* Alternative regimen (1): [[Clindamycin]] 150–300 mg PO qid 


===Osteomyelitis, prosthetic joint infection===
:* Alternative regimen (2): [[Doxycycline]] 100 mg PO qd  


===Osteomyelitis, spinal implant===
:* Alternative regimen (3): [[Erythromycin]] 400 mg PO tid 


===Osteomyelitis, vertebral===
:* Alternative regimen (4): [[Azithromycin]] 500 mg PO single dose {{then}} 250 mg PO qd for 4 days 


* Vertebral Osteomyelitis – Pathogen-Based Therapy
:* Alternative regimen (5): [[Levofloxacin]] 500 mg PO qd
:* OSSA or coagulase-negative staphylococci
::* Preferred regimen: Oxacillin 2 g IV q6h {{or}} Cefazolin 1–2 g IV q8h
::* Alternative regimen: Levofloxacin 750 mg PO qd {{and}} Rifampin 300 mg PO bid
:* ORSA
::* Preferred regimen: Vancomycin 1 g IV q12h
::* Alternative regimen (1): Daptomycin ≥ 6 mg/kg IV q24h
::* Alternative regimen (2): Levofloxacin 500–750 mg PO/IV daily {{and}} Rifampin 600–900 mg PO qd
:* Streptococcus
::* Preferred regimen: Penicillin G 5 MU IV q6h
::* Alternative regimen: Ceftriaxone 2 g IV q24h
:* Enterobacteriaceae, quinolone-susceptible
::* Preferred regimen: Ciprofloxacin 750 mg PO q12h
::* Alternative regimen: Ceftriaxone 2 g IV q24h


:* Enterobacteriaceae, quinolone-resistant
:* Alternative regimen (6): [[Moxifloxacin]] 400 mg PO qd
::* Preferred regimen: Imipenem 500 mg IV q6h
*2. '''Fungal Infection'''
:* Preferred regimen (1): Nystatin oral suspension 5–15 mL swish qid 


:* Pseudomonas aeruginosa
:* Preferred regimen (2): [[Fluconazole]] 200 mg PO qd {{then}} 100 mg q24h  
::* Preferred regimen: Cefepime 2 g IV q8h {{or}} Ceftazidime 2 g IV q8h x 2–4 wk, followed by Ciprofloxacin 750 mg PO bid
::* Alternative regimen: Piperacillin–Tazobactam 750 mg PO q12h x 2–4 wk, followed by Ciprofloxacin 750 mg PO bid
:* Anaerobes
::* Preferred regimen: Piperacillin–Tazobactam 750 mg PO q12h x 2–4 wk, followed by Ciprofloxacin 750 mg PO bid
::* Alternative regimen (1): Penicillin G 5 MU IV q6h OR Ceftriaxone 2 g IV q24h (against gram-positive anaerobes)


::* Alternative regimen (2): Metronidazole 500 mg PO tid (against gram-negative anaerobes)
:* Preferred regimen (3): [[Clotrimazole]] 10 mg PO tid for 7–10 days
*3. '''Viral Infection'''
:* Preferred regimen (1): [[Acyclovir]] 400 mg PO bid 


===Osteomyelitis, sternal===
:* Preferred regimen (2): [[Valacyclovir]] 0.5–2.0 g PO bid
:* Preferred regimen: Surgical debridement is necessary;


===Reactive arthritis, post-streptococcal  arthritis===
===Reactive arthritis, post-streptococcal  arthritis===
:* Preferred regimen: Treat strep pharyngitis and then NSAIDs ([[Prednisone]] needed in some patients)
* Reactive arthritis, post-streptococcal  arthritis <ref>{{cite book | last = Gilbert | first = David | title = The Sanford guide to antimicrobial therapy | publisher = Antimicrobial Therapy | location = Sperryville, Va | year = 2015 | isbn = 978-1930808843 }}</ref>
:* Treat strep pharyngitis and then NSAIDs ([[Prednisone]] needed in some patients)


===Reactive arthritis, Reiter's  syndrome===
===Reactive arthritis, Reiter's  syndrome===
:* Preferred regimen: Only treatment is non-steroidal anti-inflammatory drugs
* Reactive arthritis, Reiter's  syndrome <ref>{{cite book | last = Gilbert | first = David | title = The Sanford guide to antimicrobial therapy | publisher = Antimicrobial Therapy | location = Sperryville, Va | year = 2015 | isbn = 978-1930808843 }}</ref>
:* Only treatment is non-steroidal anti-inflammatory drugs


===Septic arthritis, Brucella melitensis===
===Septic arthritis, Brucella melitensis===
:* Preferred Regimen: Doxycycline 100 mg PO bid for ≥ 6 weeks {{and}} Streptomycin 15 mg/kg IM qd for 2–3 weeks OR Rifampin 600–900 mg qd for ≥ 6 weeks
* Septic arthritis, Brucella melitensis <ref>{{cite book | last = Corbel | first = Michael | title = Brucellosis in humans and animals | publisher = World Health Organization | location = Geneva | year = 2006 | isbn = 9241547138 }}</ref>
:* Alternative Regimen: Doxycycline 100 mg PO bid for ≥ 6 weeks {{and}} Gentamicin 5 mg/kg IV qd for 7 days
:* Preferred Regimen: [[Doxycycline]] 100 mg PO bid for ≥ 6 weeks {{and}} [[Streptomycin]] 15 mg/kg IM qd for 2–3 weeks {{or}} [[Rifampin]] 600–900 mg qd for ≥ 6 weeks
:* Alternative Regimen: [[Doxycycline]] 100 mg PO bid for ≥ 6 weeks {{and}} [[Gentamicin]] 5 mg/kg IV qd for 7 days


===Septic arthritis, candidal===
===Septic arthritis, candidal===
:* Preferred regime: Fluconazole 400 mg (6 mg/kg) daily for at least 6 weeks {{or}} lipid formulation of amphotericin B 3–5 mg/kg daily for several weeks, then Fluconazole to completion
* Septic arthritis, candidal <ref name="pmid19191635">{{cite journal| author=Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE et al.| title=Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. | journal=Clin Infect Dis | year= 2009 | volume= 48 | issue= 5 | pages= 503-35 | pmid=19191635 | doi=10.1086/596757 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19191635  }} </ref>
:* Alternative regime: Anidulafungin 200-mg loading dose, then 100 mg/day {{or}} [[Caspofungin]] 70-mg loading dose, then 50 mg/day {{or}} Micafungin 100 mg/day {{or}} Amphotericin B deoxycholate 0.5–1 mg/kg daily for several weeks then Fluconazole to completion
:* Preferred regimen (1): [[Fluconazole]] 400 mg/day (6 mg/kg/day) for at least 6 weeks
:* NOTE: Duration of therapy usually is for at least 6 weeks, but few data are available; Surgical debridement is recommended for all cases; For infected prosthetic joints, removal is recommended for most cases.
 
:* Preferred regimen (2): [[Amphotericin B]] 3–5 mg/kg/day for several weeks {{then}} [[Fluconazole]] to completion
:* Alternative regimen (1): [[Anidulafungin]] 200-mg loading dose {{then}} 100 mg/day
 
:* Alternative regimen (2): [[Caspofungin]] 70-mg loading dose {{then}} 50 mg/day
 
:* Alternative regimen (3): [[Micafungin]] 100 mg/day  
 
:* Alternative regimen (4): [[Amphotericin B]] deoxycholate 0.5–1 mg/kg/day for several weeks {{then}} [[Fluconazole]] to completion
:* Note: Duration of therapy usually is for at least 6 weeks, but few data are available; Surgical debridement is recommended for all cases; For infected prosthetic joints, removal is recommended for most cases.


===Septic arthritis, gonococcal===
===Septic arthritis, gonococcal===
:* Preferred regime<ref name="pmid12364368">{{cite journal| author=Shirtliff ME, Mader JT| title=Acute septic arthritis. | journal=Clin Microbiol Rev | year= 2002 | volume= 15 | issue= 4 | pages= 527-44 | pmid=12364368 | doi= | pmc=PMC126863 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12364368  }} </ref>: Ceftriaxone 1 g intramuscularly IM/IV every 24 h
* Septic arthritis, gonococcal <ref name="pmid12364368">{{cite journal| author=Shirtliff ME, Mader JT| title=Acute septic arthritis. | journal=Clin Microbiol Rev | year= 2002 | volume= 15 | issue= 4 | pages= 527-44 | pmid=12364368 | doi= | pmc=PMC126863 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12364368  }} </ref>
:* Alternative regime: Cefotaxime 1 g IV every 8 hours {{or}} Ceftizoxime 1 g IV every 8 hours
:* Preferred regimen: [[Ceftriaxone]] 1 g intramuscularly IM/IV q24h
:* NOTE: The tetracyclines (except in pregnant women) or penicillins may be used if the infecting organism is proven to be susceptible; Penicillin allergies should be given Spectinomycin (2 g IV every 12 h);Alternative antibiotics in the β-lactam-allergic patient may be Ciprofloxacin (500 mg IV every 12 h) or Ofloxacin (400 mg IV every 12 h)
:* Alternative regimen (1): [[Cefotaxime]] 1 g IV q8h 
:* Pediatric regime: (>45 kg) single daily dose of Ceftriaxone (50 mg/kg and a maximum dose of 2 g, IM or IV) for 10 to 14 days; (<45 kg) Ceftriaxone (50 mg/kg and a maximum dose of 1 g, IM or IV in a single daily dose for 7 days)
 
:* Alternative regimen (2): [[Ceftizoxime]] 1 g IV q8h
 
:* Alternative regimen (3): [[Spectinomycin]] 2 g IV q12h (Penicillin allergies)
:* Alternative regimen (4): [[Ciprofloxacin]] 500 mg IV q12h {{or}} [[Ofloxacin]] 400 mg IV q12h (β-lactam-allergic patient)
:* Note: The tetracyclines (except in pregnant women) or penicillins may be used if the infecting organism is proven to be susceptible
:* Pediatric regimen:
::* >45 kg
:::* Preferred regimen: [[Ceftriaxone]] 50 mg/kg (Maximum, 2 g/dose) IM/IV single dose for 10 to 14 days  
::* <45 kg
:::* Preferred regimen: [[Ceftriaxone]] 50 mg/kg (Maximum, 1 g/dose) IM/IV single dose for 7 days


===Septic arthritis, Gram-negative  bacilli===
===Septic arthritis, Gram-negative  bacilli===
:* Preferred regime: Ceftazidime 2 g IV q8h {{or}} Cefepime 2 g IV q8–12h {{or}} Piperacillin-Tazobactam 4.5 g IV q6h
* Septic arthritis, Gram-negative  bacilli <ref>{{cite book | last = Gilbert | first = David | title = The Sanford guide to antimicrobial therapy | publisher = Antimicrobial Therapy | location = Sperryville, Va | year = 2015 | isbn = 978-1930808843 }}</ref>
:* Preferred regimen (1): [[Ceftazidime]] 2 g IV q8h
 
:* Preferred regimen (2): [[Cefepime]] 2 g IV q8–12h
 
:* Preferred regimen (3): [[Piperacillin-Tazobactam]] 4.5 g IV q6h
:* Alternative regimen (1): [[Aztreonam]] 2 g IV q8h 
 
:* Alternative regimen (2): [[Imipenem]] 500 mg IV q6h 
 
:* Alternative regimen (3): [[Meropenem]] 1 g IV q8h 
 
:* Alternative regimen (4): [[Doripenem]] 500 mg IV q8h 


:* Alternative regime: Aztreonam 2 g IV q8h {{or}} Imipenem 500 mg IV q6h {{or}} Meropenem 1 g IV q8h {or}} Doripenem 500 mg IV q8h {{or}} Carbapenems
:* Alternative regimen (5): [[Carbapenems]]


===Septic arthritis, Histoplasmosis===
===Septic arthritis, Histoplasmosis===


* Septic arthritis, histoplasmosis<ref name="pmid17806045">{{cite journal| author=Wheat LJ, Freifeld AG, Kleiman MB, Baddley JW, McKinsey DS, Loyd JE et al.| title=Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. | journal=Clin Infect Dis | year= 2007 | volume= 45 | issue= 7 | pages= 807-25 | pmid=17806045 | doi=10.1086/521259 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17806045  }}</ref>
* Septic arthritis, histoplasmosis<ref name="pmid17806045">{{cite journal| author=Wheat LJ, Freifeld AG, Kleiman MB, Baddley JW, McKinsey DS, Loyd JE et al.| title=Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. | journal=Clin Infect Dis | year= 2007 | volume= 45 | issue= 7 | pages= 807-25 | pmid=17806045 | doi=10.1086/521259 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17806045  }}</ref>
:* Mild disease
:*1. '''Mild disease'''
::* Preferred regimen: [[Nonsteroidal anti-inflammatory drug]]
::* Preferred regimen: [[Nonsteroidal anti-inflammatory drug]]
 
:*2. '''Severe disease'''
:* Severe disease
::* Preferred regimen: [[Prednisone]] 0.5–1.0 mg/kg/day (Maximum, 80 mg/day) in tapering doses over 1–2 weeks {{and}} [[Itraconazole]] 200 mg tid for 3 days, followed by qd or bid for 6–12 weeks
::* Preferred regimen: [[Prednisone]] 0.5–1.0 mg/kg/day (maximum: 80 mg daily) in tapering doses over 1–2 weeks {{and}} [[Itraconazole]] 200 mg tid for 3 days, followed by qd or bid for 6–12 weeks


===Septic arthritis, Lyme disease===
===Septic arthritis, Lyme disease===
* Septic arthritis, Lyme disease <ref name="pmid17029130">{{cite journal| author=Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klempner MS et al.| title=The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. | journal=Clin Infect Dis | year= 2006 | volume= 43 | issue= 9 | pages= 1089-134 | pmid=17029130 | doi=10.1086/508667 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17029130  }} </ref>
* Septic arthritis, Lyme disease <ref name="pmid17029130">{{cite journal| author=Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klempner MS et al.| title=The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. | journal=Clin Infect Dis | year= 2006 | volume= 43 | issue= 9 | pages= 1089-134 | pmid=17029130 | doi=10.1086/508667 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17029130  }} </ref>
:* Patients without clinical evidence of neurologic disease
:*1. '''Patients without clinical evidence of neurologic disease'''
::* Preferred regime: Doxycycline 100 mg twice per day {{or}} Amoxicillin 500 mg 3 times per day {{or}} Cefuroxime Axetil 500 mg twice per day for 28 days
::* Preferred regimen (1): [[Doxycycline]] 100 mg bid for 28 days
::* Pediatric regime: Amoxicillin 50 mg/kg per day in 3 divided doses maximum of 500 mg per dose {{or}} Cefuroxime Axetil 30 mg/kg per day in 2 divided doses maximum of 500 mg per dose {{or}} (if the patient is ≥8 years of age) Doxycycline 4 mg/ kg per day in 2 divided doses (maximum of 100 mg per dose)
:* Patients with arthritis and objective evidence of neurologic disease
::* Preferred regime: Ceftriaxone administered parenterally for 2–4 weeks
::* Alternative regime: Cefotaxime {{or}} Penicillin G administered parenterally
::* Pediatric regime: Ceftriaxone {{or}} Cefotaxime {{or}} Penicillin G administered intravenously
:* NOTE (1): For patients who have persistent or recurrent joint swelling after a recommended course of oral antibiotic therapy, we recommend re-treatment with another 4-week course of oral antibiotics or with a 2–4-week course of Ceftriaxone IV
:* NOTE (2): If patients have no resolution of arthritis despite intravenous therapy and if PCR results for a sample of synovial fluid (and synovial tissue if available) are negative, symptomatic treatment is recommended, which consist of nonsteroidal anti-inflammatory agents, intra-articular injections of corticosteroids, or disease-modifying antirheumatic drugs (DMARDs), such as Hydroxychloroquine.


===Septic arthritis, Mycobacterium  tuberculosis===
::* Preferred regimen (2): [[Amoxicillin]] 500 mg tid for 28 days


* Septic arthritis, Mycobacterium  tuberculosis<ref>{{Cite book| edition = 4th| publisher = World Health Organization| isbn = 9789241547833| title = Treatment of Tuberculosis: Guidelines| location = Geneva| series = WHO Guidelines Approved by the Guidelines Review Committee| accessdate = 2015-06-08| date = 2010| url = http://www.ncbi.nlm.nih.gov/books/NBK138748/| pmid = 23741786}}</ref>
::* Preferred regimen (3): [[Cefuroxime axetil]] 500 mg bid for 28 days
::* Pediatric regimen (1): [[Amoxicillin]] 50 mg/kg/day tid (Maximum, 500 mg/dose)


:* Septic arthritis caused by susceptible Mycobacterium tuberculosis
::* Pediatric regimen (2): [[Cefuroxime axetil]] 30 mg/kg/day bid (Maximum, 500 mg/dose)
::* '''Intensive phase (adult)'''
:::* Preferred regimen: [[Isoniazid]] 5 mg/kg (max: 300 mg) for 2 months {{and}} [[Rifampin]] 10 mg/kg (max: 600 mg) for 2 months {{and}} [[Pyrazinamide]] 15–30 mg/kg (max: 2 g) for 2 months {{and}} [[Ethambutol]] 15–20 mg/kg (max: 1 g) for 2 months


::* '''Continuation phase (adult)'''
::* Pediatric regimen (3): (if the patient is ≥8 years of age) [[Doxycycline]] 4 mg/kg/day bid (Maximum, 100 mg/dose)
:::* Preferred regimen: [[Isoniazid]] 5 mg/kg (max: 300 mg) for 7 months {{and}} [[Rifampin]] 10 mg/kg (max: 600 mg) for 7 months
:*2. '''Patients with arthritis and objective evidence of neurologic disease'''
::* Preferred regimen: [[Ceftriaxone]] administered parenterally for 2–4 weeks
::* Alternative regimen: [[Cefotaxime]] {{or}} [[Penicillin G]] administered parenterally
::* Pediatric regimen: [[Ceftriaxone]] {{or}} [[Cefotaxime]] {{or}} [[Penicillin G]] administered intravenously
:* Note (1): For patients who have persistent or recurrent joint swelling after a recommended course of oral antibiotic therapy, we recommend re-treatment with another 4-week course of oral antibiotics or with a 2–4-week course of [[Ceftriaxone]] IV
:* Note (2): If patients have no resolution of arthritis despite intravenous therapy and if PCR results for a sample of synovial fluid (and synovial tissue if available) are negative, symptomatic treatment is recommended, which consist of nonsteroidal anti-inflammatory agents, intra-articular injections of corticosteroids, or disease-modifying antirheumatic drugs (DMARDs), such as Hydroxychloroquine.


::* '''Intensive phase (pediatric)'''
===Septic arthritis, Mycobacterium  tuberculosis===
:::* Preferred regimen: [[Isoniazid]] 10–15 mg/kg (max: 300 mg) for 2 months {{and}} [[Rifampin]] 10–20 mg/kg (max: 600 mg) for 2 months {{and}} [[Pyrazinamide]] 15–30 mg/kg (max: 2 g) for 2 months {{and}} [[Ethambutol]] 15–20 mg/kg (max: 1 g) for 2 months


::* '''Continuation phase (pediatric)'''
* Septic arthritis, Mycobacterium  tuberculosis<ref>{{Cite book| edition = 4th| publisher = World Health Organization| isbn = 9789241547833| title = Treatment of Tuberculosis: Guidelines| location = Geneva| series = WHO Guidelines Approved by the Guidelines Review Committee| accessdate = 2015-06-08| date = 2010| url = http://www.ncbi.nlm.nih.gov/books/NBK138748/| pmid = 23741786}}</ref>
:::* Preferred regimen: [[Isoniazid]] 10–15 mg/kg (max: 300 mg) for 7 months {{and}} [[Rifampin]] 10–20 mg/kg (max: 600 mg) for 7 months
:*1. '''Septic arthritis caused by susceptible Mycobacterium tuberculosis'''
 
::*1.1 '''Adults'''
:* Specific considerations
:::*1.1.1 '''Intensive phase'''
::* '''Pregnancy and breastfeeding'''
::::* Preferred regimen: [[Isoniazid]] 5 mg/kg (max, 300 mg) for 2 months {{and}} [[Rifampin]] 10 mg/kg (max: 600 mg) for 2 months {{and}} [[Pyrazinamide]] 15–30 mg/kg (max: 2 g) for 2 months {{and}} [[Ethambutol]] 15–20 mg/kg (max: 1 g) for 2 months
:::* With the exception of streptomycin, the first line anti-TB drugs are safe for use in pregnancy: streptomycin is ototoxic to the fetus and should not be used during pregnancy.
:::*1.1.2 '''Continuation phase'''
::::* Preferred regimen: [[Isoniazid]] 5 mg/kg (max: 300 mg) for 7 months {{and}} [[Rifampin]] 10 mg/kg (max: 600 mg) for 7 months
::*1.2 '''Pediatric'''
:::*1.2.1 '''Intensive phase'''
::::* Preferred regimen: [[Isoniazid]] 10–15 mg/kg (max: 300 mg) for 2 months {{and}} [[Rifampin]] 10–20 mg/kg (max: 600 mg) for 2 months {{and}} [[Pyrazinamide]] 15–30 mg/kg (max: 2 g) for 2 months {{and}} [[Ethambutol]] 15–20 mg/kg (max: 1 g) for 2 months
:::*1.2.2 '''Continuation phase'''
::::* Preferred regimen: [[Isoniazid]] 10–15 mg/kg (max: 300 mg) for 7 months {{and}} [[Rifampin]] 10–20 mg/kg (max: 600 mg) for 7 months
:*2. '''Specific considerations'''
::*2.1 '''Pregnancy and breastfeeding'''
:::* With the exception of streptomycin, the first line anti-TB drugs are safe for use in pregnancy: [[Streptomycin]] is ototoxic to the fetus and should not be used during pregnancy.
:::* After active TB in the baby is ruled out, the baby should be given 6 months of isoniazid preventive therapy, followed by BCG vaccination.
:::* After active TB in the baby is ruled out, the baby should be given 6 months of isoniazid preventive therapy, followed by BCG vaccination.
:::* Pyridoxine supplementation is recommended for all pregnant or breastfeeding women taking isoniazid.
:::* Pyridoxine supplementation is recommended for all pregnant or breastfeeding women taking isoniazid.
 
::*2.2 '''Liver disorders'''
::* '''Liver disorders'''
:::* Two hepatotoxic drugs (rather than the three in the standard regimen):
:::* Two hepatotoxic drugs (rather than the three in the standard regimen):
::::* 9 months of isoniazid and rifampicin, plus ethambutol (until or unless isoniazid susceptibility is documented).
::::* 9 months of [[Isoniazid]] {{and}} [[Rifampicin]] {{and}} [[Ethambutol]] (until or unless [[Isoniazid]] susceptibility is documented).
::::* 2 months of isoniazid, rifampicin, streptomycin and ethambutol, followed by 6 months of isoniazid and rifampicin.
::::* 2 months of [[Isoniazid]] {{and}} [[Rifampicin]] {{and}} [[Streptomycin]] {{and}} [[Ethambutol]], followed by 6 months of [[Isoniazid]] {{and}} [[Rifampicin]].
::::* 6–9 months of rifampicin, pyrazinamide and ethambutol.
::::* 6–9 months of [[Rifampicin]] {{and}} [[Pyrazinamide]] {{and}} [[Ethambutol]]
 
:::* One hepatotoxic drug:
:::* One hepatotoxic drug:
::::* 2 months of isoniazid, ethambutol and streptomycin, followed by 10 months of isoniazid and ethambutol.
::::* 2 months of [[Isoniazid]] {{and}} [[Ethambutol]] {{and}} [[Streptomycin]], followed by 10 months of [[Isoniazid]] {{and}} [[Ethambutol]]
 
:::* No hepatotoxic drugs:
:::* No hepatotoxic drugs:
::::* 18–24 months of streptomycin, ethambutol and a fluoroquinolone.
::::* 18–24 months of [[Streptomycin]] {{and}} [[Ethambutol]] {{and}} a [[Fluoroquinolone]]
 
::*2.3 '''Renal failure and severe renal insufficiency'''
::* '''Renal failure and severe renal insufficiency'''
:::* The recommended initial TB treatment regimen for patients with renal failure or severe renal insufficiency is 2 months of isoniazid, rifampicin, pyrazinamide and ethambutol, followed by 4 months of isoniazid and rifampicin.
:::* The recommended initial TB treatment regimen for patients with renal failure or severe renal insufficiency is 2 months of isoniazid, rifampicin, pyrazinamide and ethambutol, followed by 4 months of isoniazid and rifampicin.
:::* There is significant renal excretion of ethambutol and metabolites of pyrazinamide, and doses should therefore be adjusted.
:::* There is significant renal excretion of ethambutol and metabolites of pyrazinamide, and doses should therefore be adjusted.
:::* Three times per week administration of these two drugs at the following doses is recommended: pyrazinamide (25 mg/kg), and ethambutol (15 mg/kg)
:::* Three times per week administration of these two drugs at the following doses is recommended: pyrazinamide (25 mg/kg), and ethambutol (15 mg/kg)
:::* While receiving isoniazid, patients with severe renal insufficiency or failure should also be given pyridoxine in order to prevent peripheral neuropathy.
:::* While receiving isoniazid, patients with severe renal insufficiency or failure should also be given pyridoxine in order to prevent peripheral neuropathy.
:::* Because of an increased risk of nephrotoxicity and ototoxicity, streptomycin should be avoided in patients with renal failure. If streptomycin must be used, the dosage is 15 mg/kg, two or three times per week, to a maximum of 1 gram per dose, and serum levels of the drug should be monitored.
:::* Because of an increased risk of nephrotoxicity and ototoxicity, [[Streptomycin]] should be avoided in patients with renal failure. If [[Streptomycin]] must be used, the dosage is 15 mg/kg, two or three times per week, to a maximum of 1 gram per dose, and serum levels of the drug should be monitored.
 
::*2.4 '''Previously treated patients in settings with rapid DST'''
::* '''Previously treated patients in settings with rapid DST'''
:::* TB patients whose treatment has failed or other patient groups with high likelihood of multidrug-resistant TB (MDR) should be started on an empirical MDR regimen.
:::* TB patients whose treatment has failed or other patient groups with high likelihood of multidrug-resistant TB (MDR) should be started on an empirical MDR regimen.
:::* TB patients returning after defaulting or relapsing from their first treatment course may receive the retreatment regimen containing first-line drugs 2HRZES/1HRZE/5HRE if country-specific data show low or medium levels of MDR in these patients or if such data are not available.
:::* TB patients returning after defaulting or relapsing from their first treatment course may receive the retreatment regimen containing first-line drugs 2HRZES/1HRZE/5HRE if country-specific data show low or medium levels of MDR in these patients or if such data are not available.
 
::*2.5 '''TB treatment in people living with HIV'''
::* '''TB treatment in people living with HIV'''
:::* TB patients with known positive HIV status and all TB patients living in HIV prevalent settings should receive daily TB treatment at least during the intensive phase.
:::* TB patients with known positive HIV status and all TB patients living in HIV prevalent settings should receive daily TB treatment at least during the intensive phase.
:::* For the continuation phase, the optimal dosing frequency is also daily for these patients.
:::* For the continuation phase, the optimal dosing frequency is also daily for these patients.
Line 255: Line 376:


===Septic arthritis, post-intraarticular injection===
===Septic arthritis, post-intraarticular injection===
* NO empiric therapy.
* Septic arthritis, post-intraarticular injection <ref>{{cite book | last = Gilbert | first = David | title = The Sanford guide to antimicrobial therapy | publisher = Antimicrobial Therapy | location = Sperryville, Va | year = 2015 | isbn = 978-1930808843 }}</ref>
:* NO empiric therapy.


===Septic arthritis, prosthetic joint infection===
===Septic arthritis, prosthetic joint infection===


* Septic arthritis, prosthetic joint infection (device-related osteoarticular infections)
* Septic arthritis, prosthetic joint infection (device-related osteoarticular infections) <ref name="pmid23230301">{{cite journal| author=Osmon DR, Berbari EF, Berendt AR, Lew D, Zimmerli W, Steckelberg JM et al.| title=Executive summary: diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. | journal=Clin Infect Dis | year= 2013 | volume= 56 | issue= 1 | pages= 1-10 | pmid=23230301 | doi=10.1093/cid/cis966 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23230301  }} </ref>
:* Empiric antimicrobial therapy
:*1. '''Empiric antimicrobial therapy'''
::* It is preferable to delay antibiotic therapy until specimens for culture are obtained by joint aspiration, joint debridement, and/or prosthesis removal.
::* It is preferable to delay antibiotic therapy until specimens for culture are obtained by joint aspiration, joint debridement, and/or prosthesis removal.
:*2. '''Pathogen-directed antimicrobial therapy'''
::*2.1 '''Staphylococcus aureus, methicillin-susceptible (MSSA)'''
:::* Preferred regimen (1): [[Nafcillin]] 2 g IV q4–6h 


:* Pathogen-directed antimicrobial therapy
:::* Preferred regimen (2): [[Oxacillin]] 2 g IV q4–6h  
::* Staphylococcus aureus, methicillin-susceptible (MSSA)
:::* Alternative regimen (1): [[Cefazolin]] 1–2 g IV q8h
:::* Preferred regimen: [[Nafcillin]] 2 g IV q4–6h {{or}} [[Oxacillin]] 2 g IV q4–6h


:::* Alternative regimen: [[Cefazolin]] 1–2 g IV q8h {{or}} [[Ceftriaxone]] 2 g IV q24h
:::* Alternative regimen (2): [[Ceftriaxone]] 2 g IV q24h
:::* Alternative regimen (if allergic to penicillins): [[Clindamycin]] 900 mg IV q8h {{or}} [[Vancomycin]] 15–20 mg/kg IV q8–12 hours, not to exceed 2 g per dose
:::* Alternative regimen (3): (if allergic to penicillins) [[Clindamycin]] 900 mg IV q8h  


::* Staphylococcus, methicillin-resistant (MRSA)
:::* Alternative regimen (4): (if allergic to penicillins) [[Vancomycin]] 15–20 mg/kg IV q8–12h (Maximum, 2 g/dose)
:::* Early-onset (&lt; 2 months after surgery) or acute hematogenous prosthetic joint infections involving a stable implant with short duration (< 3 weeks) of symptoms and debridement (but device retention)
::*2.2 '''Staphylococcus, methicillin-resistant (MRSA)'''
:::*2.2.1 '''Early-onset or acute hematogenous prosthetic joint infections involving a stable implant with short duration (< 3 weeks) of symptoms and debridement (but device retention)'''
::::* Preferred regimen: [[Vancomycin]] {{and}} [[Rifampin]] 600 mg PO qd or 300–450 mg PO bid for 2 weeks
::::* Preferred regimen: [[Vancomycin]] {{and}} [[Rifampin]] 600 mg PO qd or 300–450 mg PO bid for 2 weeks
::::* Alternative regimen: ([[Daptomycin]] 6 mg/kg IV q24h {{or}} [[Linezolid]] 600 IV q8h) {{and}} [[Rifampin]] 600 mg PO qd or 300–450 mg PO bid for 2 weeks
::::* Alternative regimen: ([[Daptomycin]] 6 mg/kg IV q24h {{or}} [[Linezolid]] 600 IV q8h) {{and}} [[Rifampin]] 600 mg PO qd or 300–450 mg PO bid for 2 weeks
::::: Note: The above regimen should be followed by [[Rifampin]] plus a fluoroquinolone, TMP/SMX, a tetracycline or clindamycin for 3 or 6 months for hips and knees, respectively.
::::* Note: The above regimen should be followed by [[Rifampin]] plus a fluoroquinolone, TMP/SMX, a tetracycline or [[Clindamycin]] for 3 or 6 months for hips and knees, respectively.
 
:::*2.2.2 '''Early-onset spinal implant infections or implants in an actively infected site'''
:::* Early-onset spinal implant infections (&lt; 30 days after surgery), or implants in an actively infected site
::::* Initial parenteral therapy plus [[Rifampin]] followed by prolonged oral therapy is recommended.
::::* Initial parenteral therapy plus rifampin followed by prolonged oral therapy is recommended.
::::* Long-term oral suppressive antibiotics (eg, TMP-SMX, a tetracycline, a fluoroquinolone [which should be given in conjunction with [[Rifampin]] due to the potential emergence of fluoroquinolone resistance)
::::* Long-term oral suppressive antibiotics (eg, TMP-SMX, a tetracycline, a fluoroquinolone [which should be given in conjunction with rifampin due to the potential emergence of fluoroquinolone resistance)
::*2.3 '''Streptococci, beta-hemolytic'''
 
:::* Preferred regimen (1): [[Penicillin]] 12–18 MU/day IV q6h
::* Streptococci, beta-hemolytic
:::* Preferred regimen: [[Penicillin]] 12–18 MU/day IV q6h {{or}} [[Ampicillin]] 2 g IV q6h {{or}} [[Ceftriaxone]] 1–2 g IV q24h
:::* Alternative regimen (allergic to penicillin): [[Clindamycin]] 900 mg IV q8h {{or}} [[Vancomycin]] 15–20 mg/kg q8–12h, not to exceed 2 g per dose


::* Enterococci
:::* Preferred regimen (2): [[Ampicillin]] 2 g IV q6h 
:::* Monotherapy
::::* Preferred regimen (1): Ampicillin 6 to 12 g per 24 hours in four to six equally divided doses
::::* Preferred regimen (2): Penicillin G 18 to 30 million units per 24 hours either continuously or in six equally divided doses
::::* Preferred regimen (3): Vancomycin 15 to 20 mg/kg/dose every 8 to 12 hours, not to exceed 2 g per dose


:::* Combination therapy (one of the monotherapy agents, and one of the following agents)
:::* Preferred regimen (3): [[Ceftriaxone]] 1–2 g IV q24h
:::* Alternative regimen (1): (if allergic to penicillins) [[Clindamycin]] 900 mg IV q8h
:::* Alternative regimen (2): (if allergic to penicillins) [[Vancomycin]] 15–20 mg/kg IV q8–12h (Maximum, 2 g/dose)
::*2.4 '''Enterococci'''
:::*2.4.1 '''Monotherapy'''
::::* Preferred regimen (1): [[Ampicillin]] 6-12 g/day q4-6h
::::* Preferred regimen (2): [[Penicillin G]] 18-30 MU/day continuously or q4h
::::* Preferred regimen (3): [[Vancomycin]] 15-20 mg/kg/dose q8-12h (Maximum, 2 g/dose)
:::*2.4.2 '''Combination therapy (one of the monotherapy agents, and one of the following agents)'''
::::* Preferred regimen (1): [[Gentamicin]] 1 mg/kg IV q8h
::::* Preferred regimen (1): [[Gentamicin]] 1 mg/kg IV q8h
::::* Preferred regimen (2): [[Streptomycin]] 7.5 mg/kg IV q12h
::::* Preferred regimen (2): [[Streptomycin]] 7.5 mg/kg IV q12h
::::* Preferred regimen (3): [[Ampicillin]] 2 g/day IV q6h {{and}} [[Ceftriaxone]] 2 g IV q12h
::::* Preferred regimen (3): [[Ampicillin]] 2 g/day IV q6h {{and}} [[Ceftriaxone]] 2 g IV q12h
 
::*2.5 '''Gram-negative bacilli'''
::* Gram-negative bacilli
:::* Patients susceptible to fluoroquinolones
:::* Patients susceptible to fluoroquinolones
::::* Preferred regimen: Ciprofloxacin 500 to 750 mg bid
::::* Preferred regimen: [[Ciprofloxacin]] 500-750 mg bid
:::* ''P. aeruginosa''
:::*2.5.1 '''P. aeruginosa'''
::::* Preferred regimen: Cefepime 2 g intravenously every 12 hours {{or}} Meropenem 1 g intravenously every 8 hours
::::* Preferred regimen (1): [[Cefepime]] 2 g IV q12h 
::::* Alternative regimen (1): Ciprofloxacin 750 mg orally every 12 hours Ceftazidime 2 g intravenously every 8 hours (alternative)
::::* Alternative regimen (2): Ceftazidime 2 g intravenously every 8 hours


::* Anaerobes
::::* Preferred regimen (2): [[Meropenem]] 1 g IV q8h
::''Propionibacterium acnes''
::::* Alternative regimen (1): [[Ciprofloxacin]] 750 mg PO bid
:::* Preferred regimen: Penicillin 24 million units intravenously every 24 hours given in six equally divided doses or as continuous infusion {{or}} Ceftriaxone 1 to 2 g intravenously once daily
::::* Alternative regimen (2): [[Ceftazidime]] 2 g IV q8h
:::* Alternative regimen: Vancomycin {{or}} Clindamycin
::*2.6 '''Anaerobes'''
:: Not ''Propionibacterium acnes''
:::*2.6.1'''Propionibacterium acnes'''
:::* Preferred regimen: Metronidazole 500 mg orally three times a day.
::::* Preferred regimen (1): [[Penicillin]] 24 MU/day IV q4h or continuously


::* Mycobacterium tuberculosis
::::* Preferred regimen (2): [[Ceftriaxone]] 1-2 g/day IV
::::* Alternative regimen: [[Vancomycin]] {{or}} [[Clindamycin]]
:::*2.6.2 '''Not Propionibacterium acnes'''
:::* Preferred regimen: [[Metronidazole]] 500 mg PO tid
::*2.7 '''Mycobacterium tuberculosis'''
:::* Preferred regimen: see (Septic arthritis, Mycobacterium tuberculosis)
:::* Preferred regimen: see (Septic arthritis, Mycobacterium tuberculosis)
 
::*2.8 '''Fungi'''
::* Fungi
:::* Preferred regimen: see (Septic arthritis, candidal)
:::* Preferred regimen: see (Septic arthritis, candidal)
 
::*2.9 '''Culture negative'''
::* Culture negative
:::* Preferred regimen:  [[Vancomycin]] {{and}} [[Ciprofloxacin]] {{or}} [[Cefazolin]] {{and}} [[Ciprofloxacin]]
:::* Preferred regimen:  vancomycin {{and}} Ciprofloxacin {{or}} Cefazolin {{and}} Ciprofloxacin


===Septic arthritis, staphylococcal===
===Septic arthritis, staphylococcal===
''Staphylococcus aureus (methicillin-resistant)''
*1.'''Staphylococcus aureus (methicillin-resistant)'''<ref name="pmid21208910">{{cite journal| author=Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ et al.| title=Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. | journal=Clin Infect Dis | year= 2011 | volume= 52 | issue= 3 | pages= e18-55 | pmid=21208910 | doi=10.1093/cid/ciq146 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21208910  }} </ref><ref name="pmid23591823">{{cite journal| author=Sharff KA, Richards EP, Townes JM| title=Clinical management of septic arthritis. | journal=Curr Rheumatol Rep | year= 2013 | volume= 15 | issue= 6 | pages= 332 | pmid=23591823 | doi=10.1007/s11926-013-0332-4 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23591823  }} </ref><ref name=name of the journal>{{cite web | title = topic name and journal name| url =http://www.uptodate.com/contents/septic-arthritis-in-adults?source=search_result&search=Septic+arthritis&selectedTitle=1~150#H18 }}</ref>
:* Preferred regime: Vancomycin 15–20 mg/kg IV q8–12h
:* Preferred regime: [[Vancomycin]] 15–20 mg/kg IV q8–12h
 
:* Alternative regimen (1): [[Daptomycin]] 6 mg/kg IV q24h  
:* Alternative regimen (1): Daptomycin 6 mg/kg IV q24h in adults
:* Alternative regimen (2): [[Linezolid]] 600 mg PO/IV q12h
:* Alternative regimen (2): Linezolid 600 mg PO/IV q12h
:* Alternative regimen (3): [[Clindamycin]] 600 mg PO/IV q8h
 
:* Alternative regimen (4): [[TMP-SMX]] 3.5–4.0 mg/kg PO/IV q8–12h  
:* Alternative regimen (3): Clindamycin 600 mg PO/IV q8h
:* Pediatric regimen(1): [[Vancomycin]] 15 mg/kg IV q6h
:* Alternative regimen (4): TMP-SMX 3.5–4.0 mg/kg PO/IV q8–12h  
:* Pediatric regimen(1): [[Daptomycin]] 6–10 mg/kg IV q24h 
:* Pediatric regimen(1): [[Linezolid]] 10 mg/kg PO/IV q8h 
:* Pediatric regimen(1): [[Clindamycin]] 10–13 mg/kg/dose PO/IV q6–8h
2. '''Staphylococcus aureus (methicillin-susceptible)'''
:* Preferred regimen (1): [[Nafcillin]] 2 g IV q6h 


:* Pediatric regime: Vancomycin 15 mg/kg IV q6h {{or}} Daptomycin 6–10 mg/kg IV q24h {{or}} Linezolid 10 mg/kg PO/IV q8h {{or}} Clindamycin 10–13 mg/kg/dose PO/IV q6–8h
:* Preferred regimen (2): [[Clindamycin]] 900 mg IV q8h
 
:* Alternative regimen (1): [[Cefazolin]] 0.25–1 g IV/IM q6–8h  
''Staphylococcus aureus (methicillin-susceptible)''
:* Alternative regimen (2): [[Vancomycin]] 500 mg IV q6h or 1 g IV q12h
:* Preferred regime: Nafcillin 2 g IV q6h OR Clindamycin 900 mg IV q8h
3. '''Staphylococcus epidermidis (methicillin-resistant)'''
:* Alternative regime: Cefazolin 0.25–1 g IV/IM q6–8h {{or}} Vancomycin 500 mg IV q6h or 1 g IV q12h
:* Preferred regimen (1): [[Vancomycin]] 500 mg IV q6h or 1 g IV q12h  
 
:* Preferred regimen (2): [[Linezolid]] 600 mg IV q12h
''Staphylococcus epidermidis (methicillin-resistant)''
:* Alternative regimen: (TMP-SMX 3.5–4.0 mg/kg PO/IV q8–12h (TMP component) {{or}} [[Minocycline]] 200 mg PO single dose {{then}} 100 mg PO q12h) {{and}} [[Rifampin]] 300–600 mg PO/IV q12h
:* Preferred regime: Vancomycin 500 mg IV q6h or 1 g IV q12h {{or}} Linezolid 600 mg IV q12h
4. '''Staphylococcus epidermidis (methicillin-susceptible)'''
:* Alternative regime: TMP-SMX 3.5–4.0 mg/kg PO/IV q8–12h (TMP component) {{or}} Minocycline 200 mg PO x 1 dose, then 100 mg PO q12h {{and}} Rifampin 300–600 mg PO/IV q12h
:* Preferred regimen (1): [[Nafcillin]] 2 g IV q6h
 
:* Preferred regimen (2): [[Clindamycin]] 900 mg IV q8h
''Staphylococcus epidermidis (methicillin-susceptible)''
:* Alternative regimen (1): [[Cefazolin]] 0.25–1 g IV/IM q6–8h  
:* Preferred regime: Nafcillin 2 g IV q6h OR Clindamycin 900 mg IV q8h
:* Alternative regimen (2): [[Vancomycin]] 500 mg IV q6h or 1 g IV q12h
:* Alternative regime: Cefazolin 0.25–1 g IV/IM q6–8h {{or}} Vancomycin 500 mg IV q6h or 1 g IV q12h


===Septic arthritis, streptococcal===
===Septic arthritis, streptococcal===
''Streptococcus agalactiae''
1. '''Streptococcus agalactiae''' <ref>{{cite web | title = Clinical Management of Septic Arthritis| url =http://www.med.unc.edu/tarc/events/event-files/septic%20arthritis%20management.pdf }}</ref>
:* Preferred regime: Penicillin G 2 MU IV/IM q4h {{or}} Ampicillin 2 g IV q6h
:* Preferred regimen (1): [[Penicillin G]] 2 MU IV/IM q4h
 
:* Preferred regimen (2): [[Ampicillin]] 2 g IV q6h
:* Alternative regime: Clindamycin 600–1200 mg/day IV/IM q6–12h {{or}} Cefazolin 0.25–1 g IV/IM q6–8h
:* Alternative regimen (1): [[Clindamycin]] 600–1200 mg/day IV/IM q6–12h  
''Streptococcus pyogenes''
:* Alternative regimen (2): [[Cefazolin]] 0.25–1 g IV/IM q6–8h
:* Preferred regime: Penicillin G 2 MU IV/IM q4h {{or}} Ampicillin 2 g IV q6h
2. '''Streptococcus pyogenes'''
 
:* Preferred regimen (1): [[Penicillin G]] 2 MU IV/IM q4h
:* Alternative regime: Clindamycin 600–1200 mg/day IV/IM q6–12h {{or}} Cefazolin 0.25–1 g IV/IM q6–8h
:* Preferred regimen (2): [[Ampicillin]] 2 g IV q6h
:* Alternative regimen (1): [[Clindamycin]] 600–1200 mg/day IV/IM q6–12h  
:* Alternative regimen (2): [[Cefazolin]] 0.25–1 g IV/IM q6–8h


==References==
==References==
{{reflist|2}}
{{reflist|2}}

Latest revision as of 14:46, 31 July 2015

Bursitis

  • Olecranon bursitis or prepatellar bursitis [1]
  • 1. Staphylococcus aureus, methicillin-susceptible (MSSA)
  • 2. Staphylococcus aureus, methicillin-resistant (MRSA)
  • Preferred regimen (2): Linezolid 600 mg PO qd

Osteomyelitis, candidal

  • Osteomyelitis, candidal [2]
  • Preferred regimen (1): Fluconazole 400 mg/day (6 mg/kg/day) PO for 6–12 months
  • Alternative regimen (2): Caspofungin 70mg loading dose THEN 50 mg/day PO
  • Alternative regimen (3): Micafungin 100 mg/day PO
  • Alternative regimen (4): Amphotericin B deoxycholate 0.5–1 mg/kg/day PO for several weeks THEN Fluconazole for 6–12 months
  • Note: Duration of therapy usually is prolonged (6–12 months); Surgical debridement is frequently necessary

Osteomyelitis, chronic

  • 1. Chronic Osteomyelitis in Adults – Pathogen-Based Therapy [3]
  • 1.1 OSSA
  • Preferred regimen (1): Oxacillin 1.5–2 g IV q4h for 4–6 weeks
  • Preferred regimen (2): Cefazolin 1–2 g IV q8h for 4–6 weeks
  • Alternative regimen (1): Vancomycin 15 mg/kg IV q12h for 4–6 weeks
  • Alternative regimen (2): Oxacillin 1.5–2 g IV q4h for 4–6 weeks AND Rifampin 600 mg PO qd
  • 1.2 ORSA
  • Preferred regimen (1): Vancomycin 15 mg/kg IV q12h for 4–6 weeks
  • Preferred regimen (2): Daptomycin 6 mg/kg IV q24h
  • Alternative regimen (1): Linezolid 600 mg PO/IV q12h for 6 weeks ± Rifampin 600–900 mg PO qd
  • Alternative regimen (2): Levofloxacin 500–750 mg/day PO/IV ± Rifampin 600–900 mg PO qd
  • 1.3 Penicillin-sensitive Streptococcus
  • Preferred regimen (1): Penicillin G 20 MU/day IV continuously or q4h for 4–6 weeks
  • Preferred regimen (2): Ceftriaxone 1–2 g IV/IM q24h for 4–6 weeks
  • Preferred regimen (3): Cefazolin 1–2 g IV q8h for 4–6 weeks
  • Alternative regimen: Vancomycin 15 mg/kg IV q12h for 4–6 weeks
  • 1.4 Enterococcus or Streptococcus (MIC≥ 0.5 μg/mL) or Abiotrophia or Granulicatella
  • Preferred regimen (1): Penicillin G 20 MU/day IV continuously or q4h for 4–6 weeks ± Gentamicin 1 mg/kg IV/IM q8h for 1–2 weeks
  • Preferred regimen (2): Ampicillin 12 g/day IV continuously or q4h for 4–6 weeks ± Gentamicin 1 mg/kg IV/IM q8h for 1–2 weeks
  • Alternative regimen: Vancomycin 15 mg/kg IV q12h for 4–6 weeks ± Gentamicin 1 mg/kg IV/IM q8h for 1–2 weeks
  • 1.5 Enterobacteriaceae
  • Preferred regimen (1): Ceftriaxone 1–2 g IV/IM q24h for 4–6 weeks
  • Alternative regimen (2): Ciprofloxacin 500–750 mg PO bid for 4–6 weeks
  • 1.6 Pseudomonas aeruginosa
  • Preferred regimen (1): Cefepime 2 g IV q12h
  • Preferred regimen (3): Imipenem 500 mg IV q6h for 4–6 weeks
  • Alternative regimen (1): Ciprofloxacin 750 mg PO q12h
  • Alternative regimen (2): Ceftazidime 2 g IV q8h for 4–6 weeks
  • 2. Chronic Osteomyelitis in Children – Pathogen-Based Therapy
  • Group A beta-hemolytic Streptococcus, Haemophilus influenzae type B and Streptococcus pneumoniae
  • Preferred regimen (1): Ampicillin 150–200 mg/kg/day q6h

Osteomyelitis, contiguous with vascular insufficiency

  • Osteomyelitis, contiguous with vascular insufficiency [4]
  • Debride overlying ulcer and send bone specimen for histology and culture.
  • No empiric antimicrobial therapy unless acutely ill.
  • Antibiotic therapy should be based on culture results and treat for 6 weeks.
  • Revascularize if possible.

Osteomyelitis, diabetic foot

  • 1. Chronic Infection or Recent Antibiotic Use [5]
  • Preferred regimen (2): Cefoxitin 1 g IV q4h (or 2 g IV q6–8h)
  • Preferred regimen (3): Ceftriaxone 1–2 g/day IV/IM q12–24h
  • Preferred regimen (6): Ertapenem 1 g IV/IM q24h
  • Preferred regimen (7): Tigecycline 100 mg IV THEN 50 mg IV q12h (active against MRSA)
  • Preferred regimen (8): Imipenem-Cilastatin 0.5–1 g IV q6–8h (Not active against MRSA; consider when ESBL-producing pathogens suspected)
  • Alternative regimen (1): Levofloxacin 750 mg IV/PO q24h AND Clindamycin 150–300 mg PO qid
  • Alternative regimen (2): Ciprofloxacin 600–1200 mg/day IV q6–12h AND Clindamycin 150–300 mg PO qid
  • Alternative regimen (3): Ciprofloxacin 1200–2700 mg IV q6–12h (for more severe cases) AND Clindamycin 150–300 mg PO qid
  • 2. High Risk for MRSA
  • Preferred regimen (1): Linezolid 600 mg IV/PO q12h
  • Preferred regimen (3): Vancomycin 15–20 mg/kg IV q8–12h (trough: 10–20 mg/L)
  • 3. High Risk for Pseudomonas aeruginosa
  • 4. Polymicrobial Infection

Osteomyelitis, foot bone

  • Foot bone osteomyelitis due to nail through tennis shoe [6]
  • Alternative regimen (2): Cefepime 2 g IV q12h

Osteomyelitis, foot puncture wound

  • Long bone, post-internal fixation of fracture [7]
  • 1. S. aureus or P. aeruginosa
  • 2. Gm-neg. bacilli

Osteomyelitis, hematogenous

  • 1. Empiric therapy [8]
  • 1.1 Adult (>21 yrs)
  • 1.1.1 MRSA possible
  • Preferred regimen: Vancomycin 1 g IV q12h (if over 100 kg, 1.5 g IV q12h)
  • 1.1.2 MRSA unlikely
  • 1.2 Children (>4 mos.)-Adult
  • 1.2.1 MRSA possible
  • 1.2.2 MRSA unlikely
  • 1.3 Newborn (<4 mos.)
  • 1.3.1 MRSA possible
  • 1.3.2 MRSA unlikely
  • 2. Specific therapy
  • 2.1 MSSA
  • 2.2 MRSA

Osteomyelitis, hemoglobinopathy

  • Osteomyelitis, hemoglobinopathy [9]

Osteomyelitis, spinal implant

  • Culture, treat & then suppress until fusion occurs
  • Main parenteral antimicrobial therapy
  • Suppressive antimicrobial therapy strategy
  • 2. Onset after 30 days
  • Remove implant, culture & treat
  • Main parenteral antimicrobial therapy
  • Suppressive antimicrobial therapy strategy

Osteomyelitis, vertebral

  • Vertebral Osteomyelitis – Pathogen-Based Therapy [12] [13]
  • 1. OSSA or coagulase-negative staphylococci
  • 2. ORSA
  • 3. Streptococcus
  • 4. Enterobacteriaceae, quinolone-susceptible
  • 5. Enterobacteriaceae, quinolone-resistant
  • Preferred regimen: Imipenem 500 mg IV q6h
  • 6. Pseudomonas aeruginosa
  • 7. Anaerobes
  • Alternative regimen (2): Ceftriaxone 2 g IV q24h (against gram-positive anaerobes)
  • Alternative regimen (3): Metronidazole 500 mg PO tid (against gram-negative anaerobes)

Osteomyelitis, sternal

  • Osteomyelitis, sternal [14]
  • Preferred regimen: Vancomycin 1 g IV q12h (If over 100kg, 1.5 g IV q12h)
  • Alternative regimen: Linezolid 600 mg po/IVNAI bid

Osteonecrosis of the jaw

  • 1. Bacterial Infection [15]
  • Preferred regimen (1): Penicillin VK 500 mg PO q6–8h for 7–10 days (maintenance: 500 mg PO bid)
  • Preferred regimen (2): Amoxicillin 500 mg PO q8h for 7–10 days (maintenance: 500 mg PO bid)
  • Alternative regimen (1): Clindamycin 150–300 mg PO qid
  • Alternative regimen (4): Azithromycin 500 mg PO single dose THEN 250 mg PO qd for 4 days
  • 2. Fungal Infection
  • Preferred regimen (1): Nystatin oral suspension 5–15 mL swish qid
  • Preferred regimen (2): Fluconazole 200 mg PO qd THEN 100 mg q24h
  • Preferred regimen (3): Clotrimazole 10 mg PO tid for 7–10 days
  • 3. Viral Infection
  • Preferred regimen (1): Acyclovir 400 mg PO bid

Reactive arthritis, post-streptococcal arthritis

  • Reactive arthritis, post-streptococcal arthritis [16]
  • Treat strep pharyngitis and then NSAIDs (Prednisone needed in some patients)

Reactive arthritis, Reiter's syndrome

  • Reactive arthritis, Reiter's syndrome [17]
  • Only treatment is non-steroidal anti-inflammatory drugs

Septic arthritis, Brucella melitensis

  • Septic arthritis, Brucella melitensis [18]

Septic arthritis, candidal

  • Septic arthritis, candidal [2]
  • Preferred regimen (1): Fluconazole 400 mg/day (6 mg/kg/day) for at least 6 weeks
  • Alternative regimen (2): Caspofungin 70-mg loading dose THEN 50 mg/day
  • Alternative regimen (4): Amphotericin B deoxycholate 0.5–1 mg/kg/day for several weeks THEN Fluconazole to completion
  • Note: Duration of therapy usually is for at least 6 weeks, but few data are available; Surgical debridement is recommended for all cases; For infected prosthetic joints, removal is recommended for most cases.

Septic arthritis, gonococcal

  • Septic arthritis, gonococcal [19]
  • Preferred regimen: Ceftriaxone 1 g intramuscularly IM/IV q24h
  • Alternative regimen (1): Cefotaxime 1 g IV q8h
  • Alternative regimen (3): Spectinomycin 2 g IV q12h (Penicillin allergies)
  • Alternative regimen (4): Ciprofloxacin 500 mg IV q12h OR Ofloxacin 400 mg IV q12h (β-lactam-allergic patient)
  • Note: The tetracyclines (except in pregnant women) or penicillins may be used if the infecting organism is proven to be susceptible
  • Pediatric regimen:
  • >45 kg
  • Preferred regimen: Ceftriaxone 50 mg/kg (Maximum, 2 g/dose) IM/IV single dose for 10 to 14 days
  • <45 kg
  • Preferred regimen: Ceftriaxone 50 mg/kg (Maximum, 1 g/dose) IM/IV single dose for 7 days

Septic arthritis, Gram-negative bacilli

  • Septic arthritis, Gram-negative bacilli [20]
  • Preferred regimen (2): Cefepime 2 g IV q8–12h
  • Alternative regimen (2): Imipenem 500 mg IV q6h
  • Alternative regimen (3): Meropenem 1 g IV q8h
  • Alternative regimen (4): Doripenem 500 mg IV q8h

Septic arthritis, Histoplasmosis

  • Septic arthritis, histoplasmosis[21]
  • 1. Mild disease
  • 2. Severe disease
  • Preferred regimen: Prednisone 0.5–1.0 mg/kg/day (Maximum, 80 mg/day) in tapering doses over 1–2 weeks AND Itraconazole 200 mg tid for 3 days, followed by qd or bid for 6–12 weeks

Septic arthritis, Lyme disease

  • Septic arthritis, Lyme disease [22]
  • 1. Patients without clinical evidence of neurologic disease
  • Preferred regimen (1): Doxycycline 100 mg bid for 28 days
  • Preferred regimen (2): Amoxicillin 500 mg tid for 28 days
  • Pediatric regimen (3): (if the patient is ≥8 years of age) Doxycycline 4 mg/kg/day bid (Maximum, 100 mg/dose)
  • 2. Patients with arthritis and objective evidence of neurologic disease
  • Note (1): For patients who have persistent or recurrent joint swelling after a recommended course of oral antibiotic therapy, we recommend re-treatment with another 4-week course of oral antibiotics or with a 2–4-week course of Ceftriaxone IV
  • Note (2): If patients have no resolution of arthritis despite intravenous therapy and if PCR results for a sample of synovial fluid (and synovial tissue if available) are negative, symptomatic treatment is recommended, which consist of nonsteroidal anti-inflammatory agents, intra-articular injections of corticosteroids, or disease-modifying antirheumatic drugs (DMARDs), such as Hydroxychloroquine.

Septic arthritis, Mycobacterium tuberculosis

  • Septic arthritis, Mycobacterium tuberculosis[23]
  • 1. Septic arthritis caused by susceptible Mycobacterium tuberculosis
  • 1.1 Adults
  • 1.1.1 Intensive phase
  • Preferred regimen: Isoniazid 5 mg/kg (max, 300 mg) for 2 months AND Rifampin 10 mg/kg (max: 600 mg) for 2 months AND Pyrazinamide 15–30 mg/kg (max: 2 g) for 2 months AND Ethambutol 15–20 mg/kg (max: 1 g) for 2 months
  • 1.1.2 Continuation phase
  • Preferred regimen: Isoniazid 5 mg/kg (max: 300 mg) for 7 months AND Rifampin 10 mg/kg (max: 600 mg) for 7 months
  • 1.2 Pediatric
  • 1.2.1 Intensive phase
  • Preferred regimen: Isoniazid 10–15 mg/kg (max: 300 mg) for 2 months AND Rifampin 10–20 mg/kg (max: 600 mg) for 2 months AND Pyrazinamide 15–30 mg/kg (max: 2 g) for 2 months AND Ethambutol 15–20 mg/kg (max: 1 g) for 2 months
  • 1.2.2 Continuation phase
  • Preferred regimen: Isoniazid 10–15 mg/kg (max: 300 mg) for 7 months AND Rifampin 10–20 mg/kg (max: 600 mg) for 7 months
  • 2. Specific considerations
  • 2.1 Pregnancy and breastfeeding
  • With the exception of streptomycin, the first line anti-TB drugs are safe for use in pregnancy: Streptomycin is ototoxic to the fetus and should not be used during pregnancy.
  • After active TB in the baby is ruled out, the baby should be given 6 months of isoniazid preventive therapy, followed by BCG vaccination.
  • Pyridoxine supplementation is recommended for all pregnant or breastfeeding women taking isoniazid.
  • 2.2 Liver disorders
  • Two hepatotoxic drugs (rather than the three in the standard regimen):
  • One hepatotoxic drug:
  • No hepatotoxic drugs:
  • 2.3 Renal failure and severe renal insufficiency
  • The recommended initial TB treatment regimen for patients with renal failure or severe renal insufficiency is 2 months of isoniazid, rifampicin, pyrazinamide and ethambutol, followed by 4 months of isoniazid and rifampicin.
  • There is significant renal excretion of ethambutol and metabolites of pyrazinamide, and doses should therefore be adjusted.
  • Three times per week administration of these two drugs at the following doses is recommended: pyrazinamide (25 mg/kg), and ethambutol (15 mg/kg)
  • While receiving isoniazid, patients with severe renal insufficiency or failure should also be given pyridoxine in order to prevent peripheral neuropathy.
  • Because of an increased risk of nephrotoxicity and ototoxicity, Streptomycin should be avoided in patients with renal failure. If Streptomycin must be used, the dosage is 15 mg/kg, two or three times per week, to a maximum of 1 gram per dose, and serum levels of the drug should be monitored.
  • 2.4 Previously treated patients in settings with rapid DST
  • TB patients whose treatment has failed or other patient groups with high likelihood of multidrug-resistant TB (MDR) should be started on an empirical MDR regimen.
  • TB patients returning after defaulting or relapsing from their first treatment course may receive the retreatment regimen containing first-line drugs 2HRZES/1HRZE/5HRE if country-specific data show low or medium levels of MDR in these patients or if such data are not available.
  • 2.5 TB treatment in people living with HIV
  • TB patients with known positive HIV status and all TB patients living in HIV prevalent settings should receive daily TB treatment at least during the intensive phase.
  • For the continuation phase, the optimal dosing frequency is also daily for these patients.
  • If a daily continuation phase is not possible for these patients, three times weekly dosing during the continuation phase is an acceptable alternative.
  • It is recommended that TB patients who are living with HIV should receive at least the same duration of TB treatment as HIV-negative TB patients.

Septic arthritis, pneumococcal

Septic arthritis, post-intraarticular injection

  • Septic arthritis, post-intraarticular injection [24]
  • NO empiric therapy.

Septic arthritis, prosthetic joint infection

  • Septic arthritis, prosthetic joint infection (device-related osteoarticular infections) [25]
  • 1. Empiric antimicrobial therapy
  • It is preferable to delay antibiotic therapy until specimens for culture are obtained by joint aspiration, joint debridement, and/or prosthesis removal.
  • 2. Pathogen-directed antimicrobial therapy
  • 2.1 Staphylococcus aureus, methicillin-susceptible (MSSA)
  • Preferred regimen (1): Nafcillin 2 g IV q4–6h
  • Preferred regimen (2): Oxacillin 2 g IV q4–6h
  • Alternative regimen (1): Cefazolin 1–2 g IV q8h
  • Alternative regimen (2): Ceftriaxone 2 g IV q24h
  • Alternative regimen (3): (if allergic to penicillins) Clindamycin 900 mg IV q8h
  • Alternative regimen (4): (if allergic to penicillins) Vancomycin 15–20 mg/kg IV q8–12h (Maximum, 2 g/dose)
  • 2.2 Staphylococcus, methicillin-resistant (MRSA)
  • 2.2.1 Early-onset or acute hematogenous prosthetic joint infections involving a stable implant with short duration (< 3 weeks) of symptoms and debridement (but device retention)
  • Preferred regimen: Vancomycin AND Rifampin 600 mg PO qd or 300–450 mg PO bid for 2 weeks
  • Alternative regimen: (Daptomycin 6 mg/kg IV q24h OR Linezolid 600 IV q8h) AND Rifampin 600 mg PO qd or 300–450 mg PO bid for 2 weeks
  • Note: The above regimen should be followed by Rifampin plus a fluoroquinolone, TMP/SMX, a tetracycline or Clindamycin for 3 or 6 months for hips and knees, respectively.
  • 2.2.2 Early-onset spinal implant infections or implants in an actively infected site
  • Initial parenteral therapy plus Rifampin followed by prolonged oral therapy is recommended.
  • Long-term oral suppressive antibiotics (eg, TMP-SMX, a tetracycline, a fluoroquinolone [which should be given in conjunction with Rifampin due to the potential emergence of fluoroquinolone resistance)
  • 2.3 Streptococci, beta-hemolytic
  • Preferred regimen (1): Penicillin 12–18 MU/day IV q6h
  • Preferred regimen (3): Ceftriaxone 1–2 g IV q24h
  • Alternative regimen (1): (if allergic to penicillins) Clindamycin 900 mg IV q8h
  • Alternative regimen (2): (if allergic to penicillins) Vancomycin 15–20 mg/kg IV q8–12h (Maximum, 2 g/dose)
  • 2.4 Enterococci
  • 2.4.1 Monotherapy
  • Preferred regimen (1): Ampicillin 6-12 g/day q4-6h
  • Preferred regimen (2): Penicillin G 18-30 MU/day continuously or q4h
  • Preferred regimen (3): Vancomycin 15-20 mg/kg/dose q8-12h (Maximum, 2 g/dose)
  • 2.4.2 Combination therapy (one of the monotherapy agents, and one of the following agents)
  • 2.5 Gram-negative bacilli
  • Patients susceptible to fluoroquinolones
  • 2.5.1 P. aeruginosa
  • Preferred regimen (1): Cefepime 2 g IV q12h
  • 2.6 Anaerobes
  • 2.6.1Propionibacterium acnes
  • Preferred regimen (1): Penicillin 24 MU/day IV q4h or continuously
  • 2.6.2 Not Propionibacterium acnes
  • Preferred regimen: Metronidazole 500 mg PO tid
  • 2.7 Mycobacterium tuberculosis
  • Preferred regimen: see (Septic arthritis, Mycobacterium tuberculosis)
  • 2.8 Fungi
  • Preferred regimen: see (Septic arthritis, candidal)
  • 2.9 Culture negative

Septic arthritis, staphylococcal

  • 1.Staphylococcus aureus (methicillin-resistant)[26][27]
  • Preferred regime: Vancomycin 15–20 mg/kg IV q8–12h
  • Alternative regimen (1): Daptomycin 6 mg/kg IV q24h
  • Alternative regimen (2): Linezolid 600 mg PO/IV q12h
  • Alternative regimen (3): Clindamycin 600 mg PO/IV q8h
  • Alternative regimen (4): TMP-SMX 3.5–4.0 mg/kg PO/IV q8–12h
  • Pediatric regimen(1): Vancomycin 15 mg/kg IV q6h
  • Pediatric regimen(1): Daptomycin 6–10 mg/kg IV q24h
  • Pediatric regimen(1): Linezolid 10 mg/kg PO/IV q8h
  • Pediatric regimen(1): Clindamycin 10–13 mg/kg/dose PO/IV q6–8h

2. Staphylococcus aureus (methicillin-susceptible)

  • Preferred regimen (2): Clindamycin 900 mg IV q8h
  • Alternative regimen (1): Cefazolin 0.25–1 g IV/IM q6–8h
  • Alternative regimen (2): Vancomycin 500 mg IV q6h or 1 g IV q12h

3. Staphylococcus epidermidis (methicillin-resistant)

  • Preferred regimen (1): Vancomycin 500 mg IV q6h or 1 g IV q12h
  • Preferred regimen (2): Linezolid 600 mg IV q12h
  • Alternative regimen: (TMP-SMX 3.5–4.0 mg/kg PO/IV q8–12h (TMP component) OR Minocycline 200 mg PO single dose THEN 100 mg PO q12h) AND Rifampin 300–600 mg PO/IV q12h

4. Staphylococcus epidermidis (methicillin-susceptible)

  • Preferred regimen (1): Nafcillin 2 g IV q6h
  • Preferred regimen (2): Clindamycin 900 mg IV q8h
  • Alternative regimen (1): Cefazolin 0.25–1 g IV/IM q6–8h
  • Alternative regimen (2): Vancomycin 500 mg IV q6h or 1 g IV q12h

Septic arthritis, streptococcal

1. Streptococcus agalactiae [28]

  • Preferred regimen (1): Penicillin G 2 MU IV/IM q4h
  • Preferred regimen (2): Ampicillin 2 g IV q6h
  • Alternative regimen (1): Clindamycin 600–1200 mg/day IV/IM q6–12h
  • Alternative regimen (2): Cefazolin 0.25–1 g IV/IM q6–8h

2. Streptococcus pyogenes

  • Preferred regimen (1): Penicillin G 2 MU IV/IM q4h
  • Preferred regimen (2): Ampicillin 2 g IV q6h
  • Alternative regimen (1): Clindamycin 600–1200 mg/day IV/IM q6–12h
  • Alternative regimen (2): Cefazolin 0.25–1 g IV/IM q6–8h

References

  1. Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.
  2. 2.0 2.1 Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE; et al. (2009). "Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America". Clin Infect Dis. 48 (5): 503–35. doi:10.1086/596757. PMID 19191635.
  3. Spellberg B, Lipsky BA (2012). "Systemic antibiotic therapy for chronic osteomyelitis in adults". Clin Infect Dis. 54 (3): 393–407. doi:10.1093/cid/cir842. PMC 3491855. PMID 22157324.
  4. Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.
  5. Lipsky BA, Berendt AR, Cornia PB, Pile JC, Peters EJ, Armstrong DG; et al. (2013). "2012 infectious diseases society of america clinical practice guideline for the diagnosis and treatment of diabetic foot infections". J Am Podiatr Med Assoc. 103 (1): 2–7. PMID 23328846.
  6. Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.
  7. Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.
  8. Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.
  9. Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.
  10. Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.
  11. Kowalski TJ, Berbari EF, Huddleston PM, Steckelberg JM, Mandrekar JN, Osmon DR (2007). "The management and outcome of spinal implant infections: contemporary retrospective cohort study". Clin Infect Dis. 44 (7): 913–20. doi:10.1086/512194. PMID 17342641.
  12. Gentry LO (1991). "Oral antimicrobial therapy for osteomyelitis". Ann Intern Med. 114 (11): 986–7. PMID 2024868.
  13. Marschall J, Bhavan KP, Olsen MA, Fraser VJ, Wright NM, Warren DK (2011). "The impact of prebiopsy antibiotics on pathogen recovery in hematogenous vertebral osteomyelitis". Clin Infect Dis. 52 (7): 867–72. doi:10.1093/cid/cir062. PMC 3106232. PMID 21427393.
  14. Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.
  15. Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.
  16. Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.
  17. Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.
  18. Corbel, Michael (2006). Brucellosis in humans and animals. Geneva: World Health Organization. ISBN 9241547138.
  19. Shirtliff ME, Mader JT (2002). "Acute septic arthritis". Clin Microbiol Rev. 15 (4): 527–44. PMC 126863. PMID 12364368.
  20. Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.
  21. Wheat LJ, Freifeld AG, Kleiman MB, Baddley JW, McKinsey DS, Loyd JE; et al. (2007). "Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America". Clin Infect Dis. 45 (7): 807–25. doi:10.1086/521259. PMID 17806045.
  22. Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klempner MS; et al. (2006). "The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America". Clin Infect Dis. 43 (9): 1089–134. doi:10.1086/508667. PMID 17029130.
  23. Treatment of Tuberculosis: Guidelines. WHO Guidelines Approved by the Guidelines Review Committee (4th ed.). Geneva: World Health Organization. 2010. ISBN 9789241547833. PMID 23741786. Retrieved 2015-06-08.
  24. Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.
  25. Osmon DR, Berbari EF, Berendt AR, Lew D, Zimmerli W, Steckelberg JM; et al. (2013). "Executive summary: diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America". Clin Infect Dis. 56 (1): 1–10. doi:10.1093/cid/cis966. PMID 23230301.
  26. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ; et al. (2011). "Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children". Clin Infect Dis. 52 (3): e18–55. doi:10.1093/cid/ciq146. PMID 21208910.
  27. Sharff KA, Richards EP, Townes JM (2013). "Clinical management of septic arthritis". Curr Rheumatol Rep. 15 (6): 332. doi:10.1007/s11926-013-0332-4. PMID 23591823.
  28. "Clinical Management of Septic Arthritis" (PDF).